All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by AbbVie, BeOne Medicines, Johnson & Johnson, Roche, and Sobi, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out moreCreate an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
A Letter to the editor1 published in Blood on 12th October 2017 described the positive results of a long-term phase II study on the use of rituximab and bendamustine (RB) for mucosa-associated lymphoid tissue lymphoma (MALT).
MALT 2008-01 (NCT01015248) was a multicenter, prospective and non-randomized study conducted in Spain by the Grupo Español de Linfomas y Trasplantes de Médula Ósea (GELTAMO) network. The primary endpoint of the study was event-free survival (EFS) and the secondary endpoints were overall response rate (ORR), progression-free survival (PFS), overall survival (OS) and toxicities. The long-term results of this study were reported by Antonio Salar, from the Department of Hematology at the Hospital del Mar in Barcelona, Spain, and colleagues.
The authors stated that long term outcomes of RB treatment showed good efficacy at 7 years for EFS and predicted PFS for patients with MALT lymphoma. Treatment with RB was well tolerated in patients and no new safety risks emerged. Comparison was made with another study IELSG-193 previously reportedusing 5-year data with R-chlorambucil treatment and it was found that RB treatment was superior in terms of complete response, EFS and EFS in gastric and non-gastric MALT.
References
Your opinion matters
Which of the following would most increase your confidence in referring patients with R/R large B-cell lymphoma for CAR T-cell therapy?